149 related articles for article (PubMed ID: 18043580)
1. Identification of Lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles.
Naito M; Komohara Y; Ishihara Y; Noguchi M; Yamashita Y; Shirakusa T; Yamada A; Itoh K; Harada M
Br J Cancer; 2007 Dec; 97(12):1648-54. PubMed ID: 18043580
[TBL] [Abstract][Full Text] [Related]
2. Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles.
Matsueda S; Takedatsu H; Yao A; Tanaka M; Noguchi M; Itoh K; Harada M
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6933-43. PubMed ID: 16203785
[TBL] [Abstract][Full Text] [Related]
3. New polycomb group protein enhancer of zeste homolog (EZH) 2-derived peptide with the potential to induce cancer-reactive cytotoxic T lymphocytes in prostate cancer patients with HLA-A3 supertype alleles.
Minami T; Minami T; Shimizu N; Yamamoto Y; De Velasco MA; Nozawa M; Yoshimura K; Harashima N; Harada M; Uemura H
Int Immunopharmacol; 2015 May; 26(1):133-8. PubMed ID: 25819666
[TBL] [Abstract][Full Text] [Related]
4. Identification of peptide vaccine candidates sharing among HLA-A3+, -A11+, -A31+, and -A33+ cancer patients.
Takedatsu H; Shichijo S; Katagiri K; Sawamizu H; Sata M; Itoh K
Clin Cancer Res; 2004 Feb; 10(3):1112-20. PubMed ID: 14871991
[TBL] [Abstract][Full Text] [Related]
5. Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles.
Minami T; Matsueda S; Takedatsu H; Tanaka M; Noguchi M; Uemura H; Itoh K; Harada M
Cancer Immunol Immunother; 2007 May; 56(5):689-98. PubMed ID: 16937115
[TBL] [Abstract][Full Text] [Related]
6. Identification of novel Lck-derived T helper epitope long peptides applicable for HLA-A2(+) cancer patients as cancer vaccine.
Matsueda S; Shichijo S; Nagata S; Seki C; Yamada A; Noguchi M; Itoh K
Cancer Sci; 2015 Nov; 106(11):1493-8. PubMed ID: 26331453
[TBL] [Abstract][Full Text] [Related]
7. An HLA-A3-binding prostate acid phosphatase-derived peptide can induce CTLs restricted to HLA-A2 and -A24 alleles.
Terasaki Y; Shichijo S; Niu Y; Komatsu N; Noguchi M; Todo S; Itoh K
Cancer Immunol Immunother; 2009 Nov; 58(11):1877-85. PubMed ID: 19330328
[TBL] [Abstract][Full Text] [Related]
8. New peptide vaccine candidates for epithelial cancer patients with HLA-A3 supertype alleles.
Matsueda S; Takedatsu H; Sasada T; Azuma K; Ishihara Y; Komohara Y; Noguchi M; Shichijo S; Itoh K; Harada M
J Immunother; 2007 Apr; 30(3):274-81. PubMed ID: 17414318
[TBL] [Abstract][Full Text] [Related]
9. A β-tubulin 5-derived peptide induces cytotoxic T lymphocytes restricted to the HLA-A24 allele in prostate cancer patients.
Komatsu N; Terasaki Y; Moriya F; Suekane S; Noguchi M; Todo S; Itoh K; Shichijo S
Exp Ther Med; 2010 Sep; 1(5):833-839. PubMed ID: 22993607
[TBL] [Abstract][Full Text] [Related]
10. Identification of Lck-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with distant metastases.
Imai N; Harashima N; Ito M; Miyagi Y; Harada M; Yamada A; Itoh K
Int J Cancer; 2001 Oct; 94(2):237-42. PubMed ID: 11668504
[TBL] [Abstract][Full Text] [Related]
11. Capability of SART3(109-118) peptide to induce cytotoxic T lymphocytes from prostate cancer patients with HLA class I-A11, -A31 and -A33 alleles.
Mohamed ER; Naito M; Terasaki Y; Niu Y; Gohara S; Komatsu N; Shichijo S; Itoh K; Noguchi M
Int J Oncol; 2009 Feb; 34(2):529-36. PubMed ID: 19148489
[TBL] [Abstract][Full Text] [Related]
12. Cross-allele cytotoxic T lymphocyte responses against 2009 pandemic H1N1 influenza A virus among HLA-A24 and HLA-A3 supertype-positive individuals.
Liu J; Zhang S; Tan S; Yi Y; Wu B; Cao B; Zhu F; Wang C; Wang H; Qi J; Gao GF
J Virol; 2012 Dec; 86(24):13281-94. PubMed ID: 23015716
[TBL] [Abstract][Full Text] [Related]
13. Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T lymphocytes of cancer patients with distant metastases.
Harashima N; Tanaka K; Sasatomi T; Shimizu K; Miyagi Y; Yamada A; Tamura M; Yamana H; Itoh K; Shichijo S
Eur J Immunol; 2001 Feb; 31(2):323-32. PubMed ID: 11180095
[TBL] [Abstract][Full Text] [Related]
14. Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C.
Chang KM; Gruener NH; Southwood S; Sidney J; Pape GR; Chisari FV; Sette A
J Immunol; 1999 Jan; 162(2):1156-64. PubMed ID: 9916747
[TBL] [Abstract][Full Text] [Related]
15. Identification of gp100-derived, melanoma-specific cytotoxic T-lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells.
Kawashima I; Tsai V; Southwood S; Takesako K; Celis E; Sette A
Int J Cancer; 1998 Nov; 78(4):518-24. PubMed ID: 9797143
[TBL] [Abstract][Full Text] [Related]
16. Prostate-related antigen-derived new peptides having the capacity of inducing prostate cancer-reactive CTLs in HLA-A2+ prostate cancer patients.
Harada M; Matsueda S; Yao A; Ogata R; Noguchi M; Itoh K
Oncol Rep; 2004 Sep; 12(3):601-7. PubMed ID: 15289844
[TBL] [Abstract][Full Text] [Related]
17. Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinoma.
Komohara Y; Harada M; Arima Y; Suekane S; Noguchi M; Yamada A; Itoh K; Matsuoka K
Int J Oncol; 2006 Dec; 29(6):1555-60. PubMed ID: 17088996
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical study of a personalized peptide vaccination available for six different human leukocyte antigen (HLA-A2, -A3, -A11, -A24, -A31 and -A33)-positive patients with advanced cancer.
Yamada A; Noguchi M; Komatsu N; Suekane S; Yutani S; Moriya F; Mine T; Momozono K; Kawano K; Itoh K
Exp Ther Med; 2011 Jan; 2(1):109-117. PubMed ID: 22977478
[TBL] [Abstract][Full Text] [Related]
19. A new epitope peptide derived from hepatitis C virus 1b possessing the capacity to induce cytotoxic T-lymphocytes in HCV1b-infected patients with HLA-A11, -A31, and -A33.
Matsueda S; Yamada A; Takao Y; Tamura M; Komatsu N; Yutani S; Ide T; Sata M; Itoh K
Cancer Immunol Immunother; 2007 Sep; 56(9):1359-66. PubMed ID: 17265020
[TBL] [Abstract][Full Text] [Related]
20. Identification of peptides applicable as vaccines for HLA-A26-positive cancer patients.
Niu Y; Terasaki Y; Komatsu N; Noguchi M; Shichijo S; Itoh K
Cancer Sci; 2009 Nov; 100(11):2167-74. PubMed ID: 19689476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
